Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santhera Pharmaceuticals
A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.
French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.
Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.
Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Oy Juvantia Pharma Ltd